natgillin/translations-raw huggingface dataset:
Information on foetal malformations observed in the post marketing setting are provided in section 4.6 Fertility, Pregnancy and Lactation and 4.8 Undesirable Effects. 
Podatki o malformacijah ploda, ki so jih opazili v obdobju trženja, so navedeni v poglavjih 4.6 ''Plodnost, nosečnost in dojenje'' ter 4.8 ''Neželeni učinki''.
Symptoms usually resolve or improve within days after treatment discontinuation, although some patients have experienced some neurologic sequelae. 
Simptomi ponavadi izzvenijo ali se izboljšajo v nekaj dneh po prekinitvi zdravljenja, kljub temu pa so nekateri bolniki imeli nevrološke posledice.
The population pharmacokinetics were analysed in adult and pediatric patients to evaluate the effects of demographic characteristics. 
Z analizo populacijske farmakokinetike so pri odraslih in pediatričnih bolnikih ovrednotili vpliv demografskih značilnosti.
Zirabev use is not recommended in children and adolescents under the age of 18 years because the safety and benefit have not been established in these patient populations. 
Uporaba zdravila Zirabev ni priporočljiva pri otrocih in mladostnikih, mlajših od 18 let, saj varnosti in koristi zdravila pri tej populaciji bolnikov še niso dokazali.
Efficacy results for study ML18147 (ITT population) 
Preglednica 9 Rezultati učinkovitosti v študiji ML18147 (populacija ITT)
The concentration of the final bevacizumab solution should be kept within the range of 1.4 mg/ml to 16.5 mg/ml. 
Koncentracija končne raztopine bevacizumaba mora biti v razponu od 1,4 do 16,5 mg/ml.
Before initiating Zirabev, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm. 
Pred uvedbo zdravila Zirabev je treba to tveganje skrbno preučiti pri bolnikih z dejavniki tveganja, kot sta hipertenzija ali anamneza anevrizme.
● The risk of developing blood clots in your arteries (a type of blood vessel) can increase if you are over 65 years old, if you have diabetes, or if you have had previous blood clots in your arteries. 
● Tveganje za pojav krvnih strdkov v arterijah (vrsta krvne žile) se lahko poveča, če ste starejši od 65 let, imate sladkorno bolezen ali če ste v preteklosti že imeli krvne strdke v arterijah.
Description of selected serious adverse reactions 
Opis izbranih resnih neželenih učinkov
● presence of protein in your urine accompanied by swelling of your body, 
● prisotnost beljakovin v urinu, ki jo spremlja otekanje telesa,
In most cases hypertension was controlled adequately using standard antihypertensive treatment appropriate for the individual situation of the affected patient. 
V večini primerov so hipertenzijo ustrezno obvladali s standardnim antihipertenzivnim zdravljenjem, primernim za posameznega bolnika v dani situaciji.
If you experience symptoms that affect your vision or concentration, or your ability to react, do not drive and use machines until symptoms disappear. 
Če se pri vas pojavijo simptomi, ki vplivajo na vid ali koncentracijo oziroma na vašo sposobnost odzivanja, ne vozite ali uporabljajte strojev, dokler simptomi ne izginejo.
• lesions in the gums with an exposed jaw bone that does not heal and may be associated with pain and inflammation of the surrounding tissue (see the paragraphs below the list of side effects for further recommendations), 
• lezije v dlesnih z izpostavljeno čeljustnico, ki se ne pozdravi in je lahko povezana z bolečino in vnetjem okoliških tkiv (za nadaljnja priporočila glejte odstavke pod seznamom neželenih učinkov),
In addition, an independent review of the primary endpoint was also conducted. 
Dodatno so izvedli neodvisno preverjanje primarnega opazovanega dogodka.
Long term effects of the treatment with bevacizumab on fertility are unknown. 
Dolgoročni učinki zdravljenja z bevacizumabom na plodnost niso znani.
MARKETING AUTHORISATION NUMBER(S) EU/1/18/1344/001 100 mg/4 ml vial EU/1/18/1344/002 400 mg/16 ml vial 
EU/1/18/1344/001 100 mg/4 ml viala EU/1/18/1344/002 400 mg/16 ml viala
After discontinuation of bevacizumab treatment, ovarian function recovered in 86.2% of these evaluable women. 
Po prekinitvi zdravljenja z bevacizumabom se je delovanje jajčnikov obnovilo pri 86,2 % žensk, ki jih je bilo mogoče oceniti.
Monitoring of blood pressure is generally recommended during therapy. 
Med zdravljenjem je na splošno priporočljivo spremljanje krvnega tlaka.
For further information on proteinuria see section 4.4 and Proteinuria in section 4.8. 
Za dodatne informacije glede proteinurije glejte poglavje 4.4 in ''Proteinurija'' v poglavju 4.8.
These clinically significant reactions have therefore been included in Table 2 within the column entitled “Frequency Not Known.” 
Ti klinično pomembni neželeni učinki so zato v preglednici 2 razvrščeni v stolpec ''Neznana pogostnost''.
A cross-trial comparison of the efficacy and safety data is limited by differences between these studies, most notably in patient populations, previous bevacizumab exposure and chemotherapy regimens. 
Primerjava podatkov o učinkovitosti in varnosti med študijama je omejena zaradi razlik med njima, še posebej glede populacije bolnikov, predhodne izpostavljenosti bevacizumabu in kemoterapevtskih shem.
Primary analysis was performed with a data cut-off date of 12 December 2012 and is considered the final analysis Follow-up analysis was performed with a data cut-off date of 07 March 2014; all p-values are displayed for descriptive purpose only 
primarno analizo so opravili s podatki, ki so jih zajeli do 12. decembra 2012, in velja za končno analizo nadaljnjo analizo so opravili s podatki, ki so jih zajeli do 7. marca 2014; vse p-vrednosti so navedene samo v opisne namene
● if you need to undergo an invasive dental treatment or dental surgery, tell your dentist that you are being treated with Zirabev, in particular when you are also receiving or have received an injection of bisphosphonate into your blood. 
● če imate načrtovano invazivno zdravljenje zob ali zobozdravstveni poseg, povejte zobozdravniku, da se zdravite z zdravilom Zirabev, zlasti če prejemate ali ste prejeli tudi injekcijo bisfosfonata v kri.
The dose of Zirabev needed depends on your body weight and the kind of cancer to be treated. 
Potrebni odmerek zdravila Zirabev je odvisen od vaše telesne mase in vrste raka, ki ga bomo zdravili.
Zirabev may also cause changes in laboratory tests carried out by your doctor. 
Zdravilo Zirabev lahko povzroči tudi spremembe izvidov laboratorijskih preiskav, ki jih opravi zdravnik.
Major or massive pulmonary haemorrhage/haemoptysis can occur suddenly and up to two thirds of the serious pulmonary haemorrhages resulted in a fatal outcome. 
Večja ali obsežna krvavitev v pljučih/hemoptiza se lahko pojavi nenadoma in pri do dveh tretjinah resnih krvavitev v pljučih je prišlo do smrtnega izida.
The safety of reinitiating bevacizumab therapy in patients previously experiencing PRES is not known. 
Varnost ponovne uvedbe zdravljenja z bevacizumabom pri bolnikih, pri katerih se je v preteklosti že pojavil PRES, ni znana.
The addition of bevacizumab to FOLFOX-4 resulted in a statistically significant prolongation of survival. 
Dodajanje bevacizumaba shemi FOLFOX-4 je statistično pomembno podaljšalo preživetje.
Within each frequency category, adverse reactions are presented in the order of decreasing seriousness. 
Znotraj vsake skupine pogostnosti so neželeni učinki navedeni po padajoči resnosti.
Zirabev may cause damage to your unborn baby as it may stop the formation of new blood vessels. 
Zdravilo Zirabev lahko poškoduje nerojenega otroka, saj lahko zaustavi tvorbo novih krvnih žil.
Approximately 350 patients were randomised into each of the 4 trial arms in the Part II of the trial. 
V 2. delu preskušanja so v vsako od 4 skupin randomizirali približno 350 bolnikov.
You will be treated with Zirabev once every 2 or 3 weeks. 
Z zdravilom Zirabev se boste zdravili vsaka 2 ali 3 tedne.
● Your doctor should record the brand name and batch number of your medication. 
● Pomembno je, da tako vi kot zdravnik zabeležite lastniško ime in številko serije vašega zdravila.
The signs may include: difficulty in breathing or chest pain. 
Znaki so lahko: oteženo dihanje ali bolečina v prsnem košu.
● It is possible that Zirabev can cause hypersensitivity and/or infusion reactions (reactions related to your injection of the medicine). 
● Možno je, da zdravilo Zirabev povzroča preobčutljivost in/ali reakcije na infuzijo (reakcije, povezane z injiciranjem zdravila).
Relative to control arm. NR = not reached. 
NR = niso dosegli (not reached).
Adverse reactions are added to the appropriate frequency category in the tables below according to the highest incidence seen in any indication. 
Neželeni učinki so v spodnjih preglednicah razvrščeni v ustrezno skupino pogostnosti glede na največjo pogostnost, ki so jo opazili pri katerikoli indikaciji.
A total of 452 patients were randomised to receive either: 
Skupno so randomizirali 452 bolnic na prejemanje ene od naslednjih shem:
c Based on a substudy from NSABP C-08 with 295 patients d 
Na podlagi podštudije NSABP C-08 pri 295 bolnicah.
● This medicine can increase the risk of bleeding or increase the risk of problems with wound healing after surgery. 
● To zdravilo lahko poveča tveganje za krvavitve ali poveča tveganje za težave pri celjenju ran po kirurškem posegu.
There were no complete responses and 2 partial responses (MacDonald criteria). 
Popolnih odzivov na zdravljenje ni bilo, zabeležili pa so 2 delna odziva na zdravljenje (merila po MacDonaldu).
Renal thrombotic microangiopathy, which may be clinically manifested as proteinuria (not known) with or without concomitant sunitinib use. 
Žilne bolezni renalna trombotična mikroangiopatija, ki se lahko klinično kaže kot proteinurija (neznana) pri sočasnem zdravljenju s sunitinibom ali brez njega.
Best overall response ratea 
Najboljša stopnja celokupnega odziva
These efficacy data are consistent with the results from trial AVF2107g. 
Ti podatki o učinkovitosti so skladni z rezultati preskušanja AVF2107g.
• loss of body weight, 
• izgubo telesne mase,
If you are going to have an operation, if you have had major surgery within the last 28 days or if you still have an unhealed wound following surgery, you should not receive this medicine. 
Če boste operirani, če je od večjega kirurškega posega minilo manj kot 28 dni ali če se vaša rana po kirurškem posegu še ni zacelila, tega zdravila ne smete prejeti.
• dry mouth in combination with thirst and/or reduced or darkened urine, 
• suha usta v kombinaciji z žejo in/ali zmanjšanim izločanjem urina ali temnejšim urinom,
Of the 722 patients in the trial, the majority of patients had HER2-negative disease (90%), with a small number of patients with unknown (8%) or confirmed HER2-positive status (2%), who had previously been treated with or were considered unsuitable for trastuzumab therapy. 
Od 722 bolnikov v preskušanju je večina bolnikov imela HER2-negativno bolezen (90 %), manjše število bolnikov pa je imelo neznan (8 %) ali potrjen HER2-pozitiven status (2 %); bolniki so se predhodno zdravili s trastuzumabom ali pa so bili neprimerni za zdravljenje s trastuzumabom.
After discontinuation of bevacizumab treatment, ovarian function recovered in the majority of patients. 
Po prekinitvi zdravljenja z bevacizumabom se je delovanje jajčnikov pri večini bolnic obnovilo.
As maternal IgG is excreted in milk and bevacizumab could harm infant growth and development (see section 5.3), women must discontinue breast-feeding during therapy and not breast-feed for at least six months following the last dose of bevacizumab. 
Ker se materini IgG izločajo v mleko in ker bevacizumab lahko škodljivo vpliva na rast in razvoj otroka (glejte poglavje 5.3), morajo ženske med zdravljenjem dojenje prekiniti in ne smejo dojiti še vsaj 6 mesecev po zadnjem odmerku bevacizumaba.
The only variables that showed statistically significant correlations with bleeding were bevacizumab therapy and squamous cell histology. 
Edini spremenljivki, ki sta pokazali statistično pomembno povezavo s krvavitvijo, sta bili zdravljenje z bevacizumabom in ploščatocelična histologija.
Bevacizumab clearance was approximately 30% faster in patients with low levels of serum albumin and 7% faster in subjects with higher tumour burden when compared with a typical patient with median values of albumin and tumour burden. 
Očistek bevacizumaba je bil približno 30 % hitrejši pri bolnikih z nizkimi ravnmi albumina v serumu in 7 % hitrejši pri bolnikih z velikim tumorskim bremenom v primerjavi s tipičnim bolnikom z medianimi vrednostmi albumina in tumorskega bremena.
If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. 
Običajno naj shranjevanje ne bi bilo daljše od 24 ur pri temperaturi od 2 °C do 8 °C, razen če je redčenje potekalo v nadzorovanih in validiranih aseptičnih pogojih.
Patients with recent pulmonary haemorrhage/haemoptysis (> 2.5 ml of red blood) should not be treated with Zirabev. 
Bolnikov z nedavno krvavitvijo v pljučih/hemoptizo (> 2,5 ml rdeče krvi), ne smemo zdraviti z zdravilom Zirabev.
The initial dose should be delivered over 90 minutes as an intravenous infusion. 
Začetni odmerek je treba dati v obliki 90minutne intravenske infuzije.
Table 7 Key efficacy results for the superiority analysis (ITT population, trial NO16966) Endpoint (months) 
Preglednica 7 Ključni rezultati učinkovitosti glede na analizo superiornosti (populacija ITT, preskušanje NO16966)
The pharmacokinetic data for bevacizumab are available from ten clinical trials in patients with solid tumours. 
Na voljo so farmakokinetični podatki o bevacizumabu iz 10 kliničnih preskušanj pri bolnikih s solidnimi tumorji.
Median overall survival* 
mediano celokupno preživetje*
You should discuss this with your doctor. 
O tem se pogovorite z zdravnikom.
If you have conditions causing inflammation inside the abdomen (e.g. diverticulitis, stomach ulcers, colitis associated with chemotherapy), please discuss this with your doctor. 
Če imate stanje, ki povzroča trebušno vnetje (npr. divertikulitis, želodčno razjedo, s kemoterapijo povezan kolitis), se o tem pogovorite z zdravnikom.
Repeat dose toxicity studies in animals have shown that bevacizumab may have an adverse effect on female fertility (see section 5.3). 
Študije toksičnosti pri ponavljajočih odmerkih na živalih so pokazale, da ima bevacizumab lahko škodljiv vpliv na plodnost žensk (glejte poglavje 5.3).
• feeling weak and having no energy, 
• občutek oslabelosti in pomanjkanje energije,
Please let your doctor, pharmacist or nurse know if you have previously experienced problems after injections, such as dizziness/feeling of fainting, breathlessness, swelling or skin rash. 
Zdravnika, farmacevta ali medicinsko sestro obvestite, če ste v preteklosti že kdaj imeli težave po injiciranju, kot so omotica/občutek omedlevice, zasoplost, otekanje ali kožni izpuščaj.
This is consistent with results in patients in other studies of metastatic breast cancer who did not receive concurrent anthracycline treatment (NCI-CTCAE v.3) (see section 4.8). 
To je skladno z rezultati pri bolnikih v drugih študijah metastatskega raka dojk, ki niso prejemali sočasnega zdravljenja z antraciklini (NCI-CTCAE v.3) (glejte poglavje 4.8).
The highest dose tested in humans (20 mg/kg of body weight, intravenous every 2 weeks) was associated with severe migraine in several patients. 
Največji odmerek, ki so ga preskusili pri ljudeh (20 mg/kg telesne mase, intravensko vsaka 2 tedna), je bil pri več bolnikih povezan s hudo migreno.
In one clinical trial, the incidence of hypertension of grade ≥ 3 was two fold higher in patients aged > 65 years than in the younger age group (<65 years). 
V 1 kliničnem preskušanju je bila pojavnost hipertenzije stopnje ≥ 3 dvakrat večja pri bolnikih, starih > 65 let, v primerjavi s skupino mlajših bolnikov (< 65 let).
Patients should be monitored for signs and symptoms of CNS bleeding, and Zirabev treatment discontinued in cases of intracranial bleeding. 
Bolnike je treba spremljati glede znakov in simptomov krvavitve v CŽS in v primerih intrakranialne krvavitve zdravljenje z zdravilom Zirabev prekiniti.
The findings ranged from asymptomatic declines in left ventricular ejection fraction to symptomatic CHF, requiring treatment or hospitalisation. 
Ugotovljeni učinki so segali od asimptomatskega zmanjšanja iztisnega deleža levega prekata do simptomatskega KSP, ki je zahtevalo zdravljenje ali hospitalizacijo.
The pharmacokinetics of bevacizumab was linear at doses ranging from 1 to 10 mg/kg. 
Farmakokinetika bevacizumaba je bila linearna pri odmerkih v razponu od 1 do 10 mg/kg.
In studies of up to 26 weeks duration in cynomolgus monkeys, physeal dysplasia was observed in young animals with open growth plates, at bevacizumab average serum concentrations below the expected human therapeutic average serum concentrations. 
V študijah na opicah cynomolgus, ki so trajale do 26 tednov, so pri mladih živalih z odprtimi rastnimi ploščami opazili fizalno displazijo pri povprečnih koncentracijah bevacizumaba v serumu, ki so bile pod pričakovanimi povprečnimi terapevtskimi koncentracijami v serumu pri ljudeh.
• dry skin, flaking and inflammation of the skin, change in skin colour, 
• suho kožo, luščenje in vnetje kože, spremembo barve kože,
Adverse foetal outcomes were observed at all tested doses, of which the lowest dose resulted in average serum concentrations approximately 3 times larger than in humans receiving 5 mg/kg every 2 weeks. 
Neželene izide pri plodu so opazili pri vseh preskušanih odmerkih, od katerih je najmanjši odmerek povzročil približno 3-krat višje povprečne serumske koncentracije kot odmerek 5 mg/kg pri ljudeh, ki so ga prejemali vsaka 2 tedna.
● If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall. 
● Če imate ali ste imeli anevrizmo (razširitev in oslabitev stene krvne žile) ali raztrganino v steni krvne žile.
Statistically significant improvements in progression-free survival were also observed. 
Statistično pomembno izboljšanje so opazili tudi pri preživetju brez napredovanja bolezni.
Patients were stratified according to country and Motzer score and the treatment arms were shown to be well balanced for the prognostic factors. 
Bolnike so stratificirali po državah in glede na rezultat po Motzerju; glede prognostičnih dejavnikov sta bili skupini zdravljenja dobro uravnoteženi.
A high proportion of patients (approximately 62%) went on to receive a variety of nonprotocol specified anti- cancer therapies, which may have impacted the analysis of overall survival. 
Velik delež bolnikov (približno 62 %) je v nadaljevanju prejemal različna zdravila za zdravljenje novotvorb, ki jih niso določili s protokolom, kar je lahko vplivalo na analizo celokupnega preživetja.
In the chemotherapy arms, the FOLFOX-4 regimen used the same doses and schedule as shown in Table 6 for trial NO16966. 
V skupini, ki je prejemala kemoterapijo, so pri zdravljenju po shemi FOLFOX-4 uporabljali enake odmerke in shemo odmerjanja, kot prikazuje preglednica 6 za preskušanje NO16966.
Metastatic disease progression was inhibited and microvascular permeability was reduced. 
S tem so zavrli napredovanje metastatske bolezni in zmanjšali mikrovaskularno prepustnost.
The results for all secondary endpoints (investigator assessed EFS, and ORR and OS) were consistent in showing no improvement associated with the addition of bevacizumab to the RT/T arm compared with the RT/T arm alone. 
Rezultati za vse sekundarne opazovane dogodke (EFS po oceni raziskovalca, ORR in OS) so bili skladni in niso pokazali izboljšanja, povezanega z dodatkom bevacizumaba v skupini, ki je prejemala RT/T, v primerjavi s skupino, ki je prejemala samo RT/T.
In an exploratory analysis, the extent of bevacizumab benefit on overall survival was less pronounced in the subgroup of patients who did not have adenocarcinoma histology. 
V raziskovalni analizi so ugotovili, da je bila korist bevacizumaba za celokupno preživetje manj izrazita v podskupini bolnikov, ki niso imeli histologije adenokarcinoma.
Please tell your doctor if you have recently received, or are receiving, radiotherapy. 
Obvestite zdravnika, če ste pred kratkim prejeli ali prejemate zdravljenje z obsevanjem.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity (see section 5.1). 
Zdravljenje je priporočljivo nadaljevati do napredovanja osnovne bolezni ali nesprejemljive toksičnosti (glejte poglavje 5.1).
Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. 
Bevacizumab se veže na vaskularni endotelijski rastni faktor (VEGF - vascular endothelial growth factor), ki je ključno gonilo vaskulogeneze in angiogeneze, s čimer zavira vezavo VEGF na njegova receptorja Flt-1 (VEGFR-1) in KDR (VEGFR-2) na površini endotelijskih celic.
● if you have problems with wound healing following surgery, 
● če imate težave s celjenjem ran po kirurškem posegu,
• loss of appetite, 
• pomanjkanje apetita,
In adults, the results showed no significant difference in the pharmacokinetics of bevacizumab in relation to age. 
Rezultati so pokazali, da pri odraslih ni pomembnih razlik v farmakokinetiki bevacizumaba glede na starost.
0.80 (p=0.003) 95% CI (0.69; 0.93) 
0,80 (p = 0,003) 95 % IZ (0,69; 0,93)
Bevacizumab in combination with interferon alfa-2a for the first-line treatment of advanced and/ or metastatic renal cell cancer (BO17705) 
Bevacizumab v kombinaciji z interferonom alfa-2a v prvi liniji zdravljenja napredovalega in/ali metastatskega raka ledvičnih celic (BO17705)
These were most commonly NCI-CTCAE v.3 Grade 1 epistaxis that lasted less than 5 minutes, resolved without medical intervention and did not require any changes in the bevacizumab treatment regimen. 
Krvavitev je bila najpogosteje epistaksa stopnje 1 po NCI-CTCAE v.3, ki je trajala manj kot 5 minut, je izzvenela brez zdravniške pomoči in ni zahtevala sprememb režima zdravljenja z bevacizumabom.
Prior anthracyclines exposure and/or prior radiation to the chest wall may be possible risk factors for the development of CHF. 
Predhodna izpostavljenost antraciklinom in/ali predhodno obsevanje prsnega koša sta lahko morebitna dejavnika tveganja za razvoj KSP.
• blood clot in the arteries which can lead to a stroke or a heart attack, 
• krvne strdke v arterijah, ki lahko vodijo do možganske kapi ali srčnega infarkta,
• a hole in the cartilage wall separating the nostrils of the nose, 
• predrtje stene iz hrustanca, ki ločuje nosnici,
The safety and efficacy of bevacizumab, in addition to platinum-based chemotherapy, in the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC), was investigated in trials E4599 and BO17704. 
Varnost in učinkovitost bevacizumaba, ki so ga dodali kemoterapiji na osnovi platine v prvi liniji zdravljenja bolnikov z neploščatoceličnim nedrobnoceličnim rakom pljuč (NSCLC), so proučevali v preskušanjih E4599 in BO17704.
Conclusions on the impact of bevacizumab on gemcitabine pharmacokinetics cannot be drawn. 
O vplivu bevacizumaba na farmakokinetiko gemcitabina ni mogoče sklepati.
Fatal outcome was reported in approximately a third of serious cases of gastrointestinal perforations, which represents between 0.2%-1% of all bevacizumab treated patients. 
O smrtnem izidu so poročali pri približno tretjini resnih primerov perforacij prebavil, kar predstavlja med 0,2 % in 1 % vseh bolnikov, ki so se zdravili z bevacizumabom.
Infusion solutions should be used immediately after dilution. 
Infuzijsko raztopino je treba uporabiti takoj po redčenju.